Publications by authors named "D Hirt"
Article Synopsis
- The study examines how thermal conductivity in metallic nanostructures changes as their size approaches the mean free path of electrons, revealing decreased conductivity due to increased scattering.
- Matthiessen's rule, used for assessing electron scattering rates, was experimentally validated as it applies to thin copper films of varying thicknesses and structures.
- The research finds that while the electron-phonon coupling factor is consistent regardless of thickness, electronic scattering rates rise as film thickness decreases, providing insights for improving thermal management in future electronics.
Aims: Population pharmacokinetics (PK) models may be effective in improving antibiotic exposure with individualized dosing. The aim of the study is to assess cefazolin exposure using a population PK model in critically ill children.
Methods: We conducted a single-centre observational study including children under 18 years old who had cefazolin plasma monitoring before and after a cefazolin model implementation.
Cystic fibrosis is one of the most common genetic diseases among caucasian population. This disease is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene encoding for the CFTR protein. Lumacaftor, elexacaftor, tezacaftor, and ivacaftor were currently used as the treatment to Cystic fibrosis.
View Article and Find Full Text PDFAims: Vigabatrin is an antiepileptic drug used to treat some forms of severe epilepsy in children. The main adverse effect is ocular toxicity, which is related to the cumulative dose. The aim of the study is to identify an acceptable exposure range, both through the development of a population pharmacokinetic model of vigabatrin in children enabling us to calculate patient exposure and through the study of therapeutic response.
View Article and Find Full Text PDFDarunavir (DRV) is an HIV protease inhibitor commonly used as part of antiretroviral treatment regimens globally for children and adolescents. It requires a pharmacological booster, such as ritonavir (RTV) or cobicistat. To better understand the pharmacokinetics (PK) of DRV in this younger population and the importance of the RTV boosting effect, a population PK substudy was conducted within SMILE trial, where the maintenance of HIV suppression with once daily integrate inhibitor + darunavir/ritonavir in children and adolescents is evaluated.
View Article and Find Full Text PDF